Our Pricing

Saxenda vs Wegovy Comparison - Every Dose Available

Choosing between treatments requires a clear saxenda vs wegovy comparison uk that examines real clinical data, not marketing claims. At Cured Pharmacy, our UK-registered clinical team has guided thousands of patients through this decision, and we provide transparent upfront pricing with Wegovy available from £79.00 and every dose strength in stock.

How Saxenda and Wegovy Work Differently

Both Saxenda and Wegovy belong to the GLP-1 receptor agonist class, but they contain different active ingredients with distinct pharmacological profiles. Saxenda contains liraglutide, a shorter-acting GLP-1 analogue requiring daily subcutaneous injection, whilst Wegovy contains semaglutide, a longer-acting formulation administered once weekly [1].

Semaglutide in Wegovy has a modified molecular structure with an added fatty acid side chain, extending its half-life to approximately 7 days compared to liraglutide's 13-hour half-life [1]. This structural difference explains why Wegovy maintains therapeutic levels throughout the week with a single injection, whereas Saxenda requires daily administration to sustain its appetite-suppressing effects.

Both medications work by mimicking the natural GLP-1 hormone, which regulates appetite centres in the hypothalamus, slows gastric emptying, and enhances insulin secretion. However, semaglutide demonstrates higher receptor binding affinity and slower dissociation rates, contributing to its enhanced clinical efficacy in head-to-head comparisons [2].

Clinical Trial Data: Saxenda vs Wegovy Weight Loss Results

The STEP clinical trial programme for Wegovy demonstrated superior weight loss outcomes compared to historical liraglutide data. In the pivotal STEP 1 trial, participants using semaglutide 2.4mg achieved an average body weight reduction of 14.9% over 68 weeks, with 69% of participants losing at least 10% of their initial body weight [2].

By comparison, the SCALE Obesity and Prediabetes trial for Saxenda showed participants achieved an average weight loss of 8.0% over 56 weeks, with 33.1% of participants losing at least 10% of their baseline weight [3]. Whilst both treatments significantly outperformed placebo, semaglutide consistently demonstrated approximately 1.9 times greater weight reduction in comparative analyses [2][3].

These differences reflect not only the pharmacokinetic advantages of weekly versus daily dosing but also semaglutide's enhanced receptor activity. Our clinical team at Cured Pharmacy observes that patients often find the once-weekly Wegovy regimen easier to maintain long-term, which contributes to sustained weight management outcomes beyond the trial periods.

Real-World Effectiveness in UK Clinical Practice

Beyond controlled trial environments, real-world evidence from UK prescribing data shows similar patterns. Patients prescribed Wegovy demonstrate higher treatment adherence rates, partly attributable to the convenience of weekly administration. Our superintendent pharmacist Tarun Kumar notes that adherence is a critical predictor of long-term success, and the reduced injection frequency with Wegovy addresses one of the most common barriers to sustained GLP-1 therapy.

Dosing Schedules and Titration Protocols

Saxenda follows a daily escalation protocol starting at 0.6mg, increasing by 0.6mg increments every week until reaching the maintenance dose of 3.0mg daily [3]. This gradual titration helps minimise gastrointestinal side effects, though it requires consistent daily injections and careful dose tracking by patients.

Wegovy uses a more extended titration schedule over 16-20 weeks, starting at 0.25mg weekly and increasing through 0.5mg, 1.0mg, 1.7mg, before reaching the target maintenance dose of 2.4mg weekly [2]. Each dose strength is maintained for at least 4 weeks, allowing the body to adapt and reducing the incidence of nausea and vomiting that can occur with faster escalation.

At Cured Pharmacy, we stock every dose strength for both medications, ensuring seamless progression through your titration schedule without supply interruptions. Your UK prescriber will determine the appropriate starting dose and escalation timeline based on your medical history, current medications, and tolerability during your free online consultation.

What Happens If You Miss a Dose

With Saxenda's daily regimen, missing doses can disrupt therapeutic levels and may trigger withdrawal symptoms or renewed appetite. With Wegovy's weekly schedule, patients have more flexibility—if you miss your injection day, you can administer it within 5 days of the scheduled dose without restarting titration [2]. This built-in flexibility makes Wegovy more forgiving for patients with variable schedules.

Side Effect Profiles: What to Expect from Each Treatment

Both medications share a similar side effect profile dominated by gastrointestinal symptoms, as expected with GLP-1 receptor agonists. The most commonly reported adverse effects include nausea, diarrhoea, constipation, vomiting, and abdominal discomfort, typically most pronounced during dose escalation phases [2][3].

Clinical trial data shows that nausea occurred in approximately 44% of Wegovy users versus 39% of Saxenda users, though the weekly dosing pattern of Wegovy may concentrate side effects in the 24-48 hours post-injection rather than maintaining constant low-level symptoms [2][3]. Many patients report that side effects diminish significantly after 4-6 weeks at each dose level as the body adapts.

Serious adverse events are rare but include potential pancreatitis, gallbladder disease, and hypoglycaemia (particularly in patients taking concurrent diabetes medications). Both treatments carry a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though no causal relationship has been established in humans [1][2]. Your UK prescriber will screen for contraindications including personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 during your clinical assessment.

Cost Comparison: Saxenda vs Wegovy UK Pricing

Pricing represents a significant consideration when choosing between these treatments, as both require ongoing monthly expenditure for sustained weight management. At Cured Pharmacy, we offer transparent upfront pricing with Wegovy available from £79.00, representing competitive UK pricing compared to typical market rates.

When evaluating cost-effectiveness, consider the dosing frequency and average duration of treatment required to achieve clinically meaningful weight loss. Wegovy's superior efficacy in clinical trials means some patients may reach their target weight loss goals more quickly, potentially reducing overall treatment duration. However, individual responses vary considerably, and your UK prescriber will monitor your progress to optimise both clinical outcomes and cost-effectiveness.

All prices shown at Cured Pharmacy are displayed before you begin your consultation, eliminating unexpected costs. Our lowest price guarantee ensures you receive genuine UK-licensed medications at the most competitive rates available from a registered UK pharmacy. Remember that all prescription weight loss treatments require ongoing clinical assessment by a UK prescriber to ensure safety and appropriateness.

Insurance and NHS Availability

NHS availability for both treatments remains limited, with strict eligibility criteria typically requiring BMI ≥35 with comorbidities or BMI ≥40, alongside participation in specialist weight management services. Private prescription through registered online pharmacies like Cured Pharmacy offers faster access with broader eligibility, subject to clinical appropriateness as determined by your prescriber during consultation.

Which Treatment Is Right for You: Saxenda vs Wegovy

The optimal choice between Saxenda and Wegovy depends on multiple factors including your weight loss goals, lifestyle considerations, previous treatment responses, medical history, and budget. Patients who prefer less frequent injections and are seeking maximum weight loss efficacy based on clinical trial data may find Wegovy more suitable, whilst those who have previously responded well to daily GLP-1 therapy may prefer continuing with a familiar regimen.

Your medical history plays a crucial role in this decision. Patients with a history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy may require additional monitoring or may not be suitable candidates for GLP-1 therapy. Additionally, both medications are contraindicated in pregnancy, and reliable contraception is essential for women of childbearing potential throughout treatment [1][2][3].

At Cured Pharmacy, our UK-registered clinical team conducts thorough online assessments to determine which treatment aligns with your individual circumstances. The consultation takes under 3 minutes to complete, and our prescribers review your medical history, current medications, and weight loss objectives to recommend the most appropriate option. If prescribed, your medication is dispensed by our GPhC-registered pharmacy and delivered in 100% discreet packaging to your chosen address.

Starting Your Weight Loss Journey with Cured Pharmacy

Beginning treatment is straightforward: complete the free online consultation, receive a clinical decision from a UK prescriber, and if approved, your prescribed medication is prepared by superintendent pharmacist Tarun Kumar (GPhC 2233073) and dispatched promptly. We stock every dose strength for seamless titration, and our clinical team remains available at (+44) 116 4646009 should you have questions during your treatment journey.

Scientific References

1. Knudsen, L. B., & Lau, J. (2019). The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology, 10, 155. https://doi.org/10.3389/fendo.2019.00155
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
4. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
5. Medicines and Healthcare products Regulatory Agency (MHRA). (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Public Assessment Report. GOV.UK.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals, and outcomes cannot be guaranteed. Saxenda and Wegovy are licensed treatments for weight management in adults with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities, used alongside a reduced-calorie diet and increased physical activity.